Literature DB >> 9266267

Life-threatening infection with multiresistant Staphylococcus epidermidis in a patient with end-stage renal disease: cure with chloramphenicol and quinupristin/dalfopristin (RP 59500).

E Mündlein1, H von Baum, H K Geiss, M Springsklee, M Zeier, K Andrassy.   

Abstract

A 45-year-old man with end-stage renal disease underwent a cadaveric kidney transplantation. The allograft had to he removed 10 days after transplantation because of an acute vascular rejection. After explantation, the patient suffered from a life-threatening infection with Staphylococcus epidermidis involving lungs, eyes and liver for 11 months. Despite adequate therapy including vancomycin followed by teicoplanin, he developed spondylodiscitis requiring repeated surgical interventions. The definitive cure was achieved by a sequential therapy with chloramphenicol and quinupristin/dalfopristin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266267     DOI: 10.1007/bf01713157

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

Review 1.  Penetration into tissues of various drugs active against gram-positive bacteria.

Authors:  A Kropec; F D Daschner
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

2.  Hepatic fibrin-ring granulomas caused by Staphylococcus epidermidis generalized infection.

Authors:  J Font; M Bruguera; F Perez-Villa; M Ingelmo
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

3.  Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin.

Authors:  W A Lynn; E Clutterbuck; S Want; V Markides; S Lacey; T R Rogers; J Cohen
Journal:  Lancet       Date:  1994-10-08       Impact factor: 79.321

4.  Trends in antimicrobial drug prescribing among office-based physicians in the United States.

Authors:  L F McCaig; J M Hughes
Journal:  JAMA       Date:  1995-01-18       Impact factor: 56.272

5.  Efficacy, tolerability and pharmacokinetics of teicoplanin in patients undergoing breast surgery.

Authors:  K Exner; E Lang; A Borsche; G Lemperle
Journal:  Eur J Surg Suppl       Date:  1992

Review 6.  The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens.

Authors:  F C Tenover; J M Hughes
Journal:  JAMA       Date:  1996 Jan 24-31       Impact factor: 56.272

  6 in total
  1 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.